FY2025 EPS Estimates for SLNO Raised by Cantor Fitzgerald

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2025 EPS estimates for shares of Soleno Therapeutics in a note issued to investors on Wednesday, July 16th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will earn ($2.10) per share for the year, up from their prior forecast of ($3.44). Cantor Fitzgerald currently has a "Overweight" rating and a $123.00 target price on the stock. The consensus estimate for Soleno Therapeutics' current full-year earnings is ($3.72) per share. Cantor Fitzgerald also issued estimates for Soleno Therapeutics' FY2026 earnings at $0.84 EPS.

Several other equities research analysts have also recently commented on the company. UBS Group set a $105.00 price objective on Soleno Therapeutics in a research report on Thursday, March 27th. HC Wainwright restated a "buy" rating and set a $100.00 price objective on shares of Soleno Therapeutics in a research report on Tuesday, April 15th. Robert W. Baird set a $121.00 price objective on shares of Soleno Therapeutics and gave the company an "outperform" rating in a research report on Friday, July 11th. Cowen began coverage on Soleno Therapeutics in a research report on Monday, June 23rd. They set a "buy" rating for the company. Finally, Stifel Nicolaus upped their price objective on Soleno Therapeutics from $74.00 to $108.00 and gave the company a "buy" rating in a research report on Friday, March 28th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $108.70.

Soleno Therapeutics Stock Performance

Shares of Soleno Therapeutics stock traded up $1.22 during trading on Friday, hitting $88.42. 199,281 shares of the company's stock traded hands, compared to its average volume of 853,781. The company has a debt-to-equity ratio of 0.21, a current ratio of 19.64 and a quick ratio of 19.64. Soleno Therapeutics has a 1 year low of $41.50 and a 1 year high of $90.32. The stock has a market capitalization of $4.46 billion, a P/E ratio of -19.14 and a beta of -2.63. The business has a 50-day simple moving average of $79.81 and a 200-day simple moving average of $64.30.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.19.

Hedge Funds Weigh In On Soleno Therapeutics

Institutional investors have recently made changes to their positions in the company. AlphaQuest LLC increased its stake in shares of Soleno Therapeutics by 1,154.4% during the fourth quarter. AlphaQuest LLC now owns 715 shares of the company's stock valued at $32,000 after buying an additional 658 shares during the period. Quarry LP purchased a new position in Soleno Therapeutics during the 1st quarter worth $121,000. Springhill Fund Asset Management HK Co Ltd purchased a new stake in shares of Soleno Therapeutics during the fourth quarter worth about $81,000. Avanza Fonder AB increased its stake in Soleno Therapeutics by 14.8% during the 1st quarter. Avanza Fonder AB now owns 1,951 shares of the company's stock valued at $144,000 after purchasing an additional 251 shares in the last quarter. Finally, Summit Investment Advisors Inc. lifted its position in Soleno Therapeutics by 24.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 2,677 shares of the company's stock worth $120,000 after acquiring an additional 522 shares during the period. Hedge funds and other institutional investors own 97.42% of the company's stock.

Insider Buying and Selling

In related news, insider Patricia C. Hirano sold 3,830 shares of the firm's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $82.76, for a total value of $316,970.80. Following the transaction, the insider owned 13,206 shares of the company's stock, valued at $1,092,928.56. This trade represents a 22.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 6.40% of the stock is owned by corporate insiders.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.